Interpace Diagnostics Group Inc (NASDAQ:IDXG) granted to Jack E. Stover, the Company’s President and Chief Executive Officer, and James Early, the Company’s Chief Financial Officer, awards of incentive stock options to purchase 326,368 and 80,000, respectively, shares of the Company’s common stock. The awards were granted pursuant to the Company’s Amended and Restated 2004 Stock Award and Incentive Plan (the “Plan”). The option awards have an exercise price of $0.16 per share, representing the closing sales price for shares of the Company’s common stock on The NASDAQ Capital Market on October 14, 2016, the date of grant, and, subject generally to the executive’s continued service with the Company, vest in equally monthly installments over a period of one year, subject to 100% vesting acceleration upon the occurrence of a Change in Control (as such term is defined in the Plan). Each of Messrs. Stover and Early has entered into an Incentive Stock Option Agreement with the Company with respect to the executive’s respective option award, copies of which agreements are filed as Exhibit 10.1 and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
